Case studies on clinical evaluation of biosimilar monoclonal antibody: Scientific considerations for regulatory approval
- 1 January 2015
- journal article
- review article
- Published by Elsevier in Biologicals
- Vol. 43 (1) , 1-10
Abstract
No abstract availableKeywords
This publication has 13 references indexed in Scilit:
- U.S. Food and Drug Administration Approval: Obinutuzumab in Combination with Chlorambucil for the Treatment of Previously Untreated Chronic Lymphocytic LeukemiaClinical Cancer Research, 2014
- Safety with Ocrelizumab in Rheumatoid Arthritis: Results from the Ocrelizumab Phase III ProgramPLOS ONE, 2014
- WHO/KFDA joint workshop on implementing WHO guidelines on evaluating similar biotherapeutic products, Seoul, Republic of Korea 24–26 August, 2010Biologicals, 2011
- Infliximab: 12 years of experienceArthritis Research & Therapy, 2011
- Acceptable changes in quality attributes of glycosylated biopharmaceuticalsNature Biotechnology, 2011
- Ocrelizumab, a humanized anti‐CD20 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: A phase I/II randomized, blinded, placebo‐controlled, dose‐ranging studyArthritis & Rheumatism, 2008
- Rituximab for rheumatoid arthritis refractory to anti–tumor necrosis factor therapy: Results of a multicenter, randomized, double‐blind, placebo‐controlled, phase III trial evaluating primary efficacy and safety at twenty‐four weeksArthritis & Rheumatism, 2006
- Two Immunoglobulin G Fragment C Receptor Polymorphisms Independently Predict Response to Rituximab in Patients With Follicular LymphomaJournal of Clinical Oncology, 2003
- The mechanisms of action of rituximab in the elimination of tumor cellsSeminars in Oncology, 2003
- Mechanism of action of rituximabAnti-Cancer Drugs, 2002